$25.42
+0.56(2.25%)
Mkt Cap $318M
$5.25
$35.53
52-Week Range
At a Glance
AI-generatedForte Biosciences deepened its operating and net losses in 2025 amid sustained clinical investments in its pre-revenue development stage, with cash burn accelerating due to higher operating expenses while EPS improved from prior-year levels on increased share count.
8-K
Forte Biosciences reported a full year 2025 net loss of $69.4 million, driven by increased R&D spending for FB102 clinical trials, ending the year with $77.0 million in cash.$318M
Market Cap
—
Revenue
-$36M
Net Income
Employees14
Fundamentals
How The Business Makes Money
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001419041
ISINUS34962G2084
CUSIP34962G109
Phone310 618 6994
Address3060 Pegasus Park Drive, Dallas, TX, 75247, US
SEC EDGAR